Compare Summit Therapeutics Inc (SMMT) vs Trip.com Group Ltd (TCOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Trip.com Group Ltd — how do they compare? Summit Therapeutics Inc trades at $17.38 (market cap $13.71B), while Trip.com Group Ltd trades at $38.66 (market cap $23.75B). The key difference: Trip.com Group Ltd is the larger of the two by market cap, and Trip.com Group Ltd pays a 0.42% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Summit Therapeutics Inc for 16 Days and Trip.com Group Ltd for 79 Days on average.
| SMMT | TCOM | |
|---|---|---|
Market Cap | $13.71B | $23.75B |
Volume | 6,173,057 | 2,089,737 |
Sector | Health | Consumer Cyclical |
52-Week High | $26.38 | $78.96 |
52-Week Low | $12.43 | $37.96 |
Typical Hold Time | 16 Days | 79 Days |
Enterprise Value | $13.04B | $15.91B |
Dividend Yield | — | 0.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $17.95, up 3.7% with strong technical momentum and bullish analyst sentiment. The stock shows negative profitability metrics but benefits from AstraZeneca's $2 billion strategic investment and clinical collaborations. Recent news highlights positive clinical trial results for ivonescimab, driving investor optimism despite current financial losses.
The outlook remains speculative with significant upside potential based on analyst consensus targets averaging $29.33, though high valuation multiples and negative cash flows present substantial risk. Success of clinical trials and partnership execution will determine long-term value creation for shareholders.
Trip.com Group (TCOM) trades at $38.09, down 0.44% on the day, with technical indicators showing bearish momentum despite oversold RSI readings. The company demonstrates strong fundamentals with revenue growth from $53.3B in 2024 to $62.4B in 2025 and robust net income margins of 36.9%. Recent Q2 2026 earnings beat expectations with $1.07 EPS versus $0.98 expected, though regulatory headwinds from Chinese antitrust actions create uncertainty.
The investment outlook remains positive given attractive valuations (P/E 7.36, EV/EBITDA 3.55) and analyst consensus price target of $56.64 representing 49% upside. However, regulatory risks and competitive pressures from dismantled ranking algorithms require monitoring. With 70% analyst buy ratings and strong cash flow generation, TCOM offers value for patient investors despite near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Trip.com Group Ltd
Trip.com is the largest online travel agent in China and is positioned to benefit from the country's rising demand for higher-margin outbound travel as passport penetration is only 12% in China. The company generated about 78% of sales from accommodation reservations and transportation ticketing in 2020. The rest of revenue comes from package tours and corporate travel. Prior to the pandemic in 2019, the company generated 25% of revenue from international business, which is important to its margin expansion. Most of sales come from websites and mobile platforms, while the rest come from call centers. The competes in a crowded OTA industry in China, including Meituan, Alibaba-backed Fliggy, Toncheng, and Qunar. The company was founded in 1999 and listed on the Nasdaq in December 2003.
Read more on TCOM →
